Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.
馬薩諸塞州劍橋,2024年5月13日 /PRNewswire/ — 專注於開發靶向和免疫腫瘤學療法的生物技術公司Leap Therapeutics, Inc.(納斯達克股票代碼:LPTX)今天公佈了截至2024年3月31日的第一季度財務業績。
Leap Highlights:
飛躍亮點:
Completed $40 million private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital
Presented clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC), at the 2024 ASCO Gastrointestinal Cancers Symposium
Expanded the ongoing randomized controlled Part B of the DeFianCe study from 130 patients to 180 patients to enhance the statistical power for patients with left-sided CRC; enrollment now expected to be completed in late Q3 or early Q4 2024
Completed enrollment in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in combination with tislelizumab and chemotherapy in patients with advanced gastroesophageal junction (GEJ) and gastric cancer; first randomized controlled data for DKN-01 expected in the second half of 2024 or early 2025
在專注於生命科學的投資者吉利德科學公司、Samsara BioCapital、683 Capital Partners、LP、Laurion Capital Management和Rock Springs Capital的參與下,完成了4000萬美元的私募融資
在 2024 年 ASCO 胃腸道癌症研討會上,介紹了 2 期 DeFiance 研究 A 部分的臨床數據,該研究評估 DKN-01 與標準護理貝伐珠單抗和化療聯合治療晚期結直腸癌 (CRC) 二線患者
將正在進行的DeFiance研究的B部分隨機對照從130名患者擴大到180名患者,以增強左側結直腸癌患者的統計能力;現在的入組工作預計將於2024年第三季度末或第四季度初完成
完成了評估晚期胃食管交界處 (GEJ) 和胃癌患者的 DKN-01 與替雷利珠單抗聯合化療的隨機對照 C 部分的入組;DKN-01 的首批隨機對照數據預計將在 2024 年下半年或 2025 年初公佈
"We appreciate the strong support of Gilead and the new and existing institutional investors who participated in our recent $40 million financing that will enable the expansion and continued execution of the DKN-01 development program," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "The financing provides cash runway into the second quarter of 2026, allowing the expansion of Part B of the DeFianCe CRC study to 180 patients, the full maturation of data in Part C of the DisTinGuish GEJ/gastric cancer study, and the manufacturing of Phase 3 clinical trial material. We are well positioned for continued success and look forward to achieving major clinical milestones in the year ahead."
Leap總裁兼首席執行官道格拉斯·昂西表示:“我們感謝吉利德以及參與我們最近4000萬美元融資的新老機構投資者的大力支持,這將使 DKN-01 開發計劃的擴展和持續執行成爲可能。”“這筆融資爲2026年第二季度提供了現金流,使DeFiance CRC研究的B部分得以擴大到180名患者,DiFiance GEJ/胃癌研究C部分的數據完全成熟,以及3期臨床試驗材料的製造。我們爲持續取得成功做好了充分的準備,並期待在來年實現重要的臨床里程碑。”
Business Update:
業務更新:
Completed a $40 million private placement. In April 2024, Leap entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise of the pre-funded warrants, in a private placement. Gross proceeds from the private placement were approximately $40 million with participation from new and existing investors, including Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital. The net proceeds from this financing, combined with existing cash, cash equivalents and marketable securities, are expected to fund Leap's operating and capital expenditures into the second quarter of 2026 and enable expansion of the DKN-01 DeFianCe clinical trial and development program.
完成了4000萬美元的私募配售。2024年4月,Leap與一組精選的機構投資者簽訂了證券購買協議,以每股2.82美元的價格發行和出售總共12,660,993股普通股(“普通股”),並預先籌集資金的認股權證,以每股2.819美元的價格購買1,523,404股普通股,以私募方式發行。私募的總收益約爲4000萬美元,新老投資者參與其中,包括專注於生命科學的投資者吉利德科學公司、Samsara BioCapital、683 Capital Partners、LP、Laurion Capital Management和Rock Springs Capital。本次融資的淨收益,加上現有的現金、現金等價物和有價證券,預計將爲Leap的運營和資本支出提供資金,直至2026年第二季度,並使 DKN-01 DeFiance臨床試驗和開發計劃的擴張成爲可能。
DKN-01 Development Update
DKN-01 開發更新
Presented initial clinical data from Part A of the DeFianCe Study of DKN-01 plus bevacizumab and chemotherapy in colorectal cancer (CRC) patients. The Company presented initial data from Part A of the DeFianCe study (NCT05480306), a Phase 2 study evaluating DKN-01 in combination with standard of care (SOC) bevacizumab and chemotherapy in second-line (2L) patients with advanced microsatellite stable (MSS) CRC patients at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held in San Francisco on January 18-20, 2024 and during the Company's conference call on January 23, 2024.
提供了DeFiance研究A部分的初步臨床數據,該研究針對結直腸癌(CRC)患者的 DKN-01 加貝伐珠單抗和化療。該公司提供了來自Defiance研究A部分的初步數據(NCT05480306),這是一項2期研究,在2024年1月18日至20日在舊金山舉行的2024年美國臨床腫瘤學會(ASCO)胃腸道癌研討會以及2024年1月23日公司電話會議上,評估了對晚期微衛星穩定(MSS)結直腸癌患者二線(2L)患者聯合使用 DKN-01 與標準護理(SOC)貝伐珠單抗和化療。
-
Key Findings (as of the December 6, 2023 data cutoff):
-
Across all patients enrolled (n=33):
Overall response rate (ORR) among response-evaluable patients (n=27) was 30% and disease control rate (DCR) was 93%, including 8 partial responses (PR) and 17 patients with a best response of stable disease (SD)
Median progression-free survival (PFS) was 6.3 months
9 patients remained on therapy and were beyond 8.5 months
-
Enhanced activity in patients with left-sided tumors (n=25), a group that has more frequent activation of the Wnt pathway modulated by DKK1
33% ORR and 100% DCR in response-evaluable population (7 PRs, 14 SDs)
Preliminary median PFS of 8.6 months (9 patients continuing therapy within subgroup)
-
Compelling ORR, DCR and PFS in patients with rectal/rectosigmoid carcinomas (n=15), a population with increasing incidence among young people and shown to have the highest DKK1 levels:
46% ORR and 100% DCR in response-evaluable population (6 PRs, 7 SDs)
Preliminary median PFS of 9.4 months (6 patients continuing therapy within subgroup)
Higher baseline plasma DKK1 levels correlated with improved responses
-
DKN-01 plus bevacizumab and chemotherapy was well-tolerated, with a majority of DKN-01 related events being low grade (Grade 1/2)
-
主要調查結果(截至2023年12月6日數據截止日期):
-
在所有入組患者中(n=33):
反應可評估患者(n=27)的總緩解率(ORR)爲30%,疾病控制率(DCR)爲93%,包括8名部分反應(PR)和17名對穩定疾病(SD)反應最佳的患者
中位無進展存活率 (PFS) 爲 6.3 個月
9 名患者仍在接受治療,療程已超過 8.5 個月
-
左側腫瘤患者的活性增強(n=25),該群體更頻繁地激活由 DKK1 調節的 Wnt 通路
在反應可評估人群中,ORR 爲 33% 和 100% DCR(7 個 PR,14 個 SD)
初步中位PFS爲8.6個月(亞組中有9名患者繼續治療)
-
直腸/直腸乙狀結腸癌患者中引人注目的ORR、DCR和PFS(n=15),該人群在年輕人中的發病率不斷上升,且顯示其DKK1水平最高:
反應可評估人群中 46% 的 ORR 和 100% 的 DCR(6 個 PR,7 個 SD)
初步中位PFS爲9.4個月(亞組內有6名患者繼續治療)
較高的基線血漿 DKK1 水平與反應改善相關
-
DKN-01 加貝伐珠單抗和化療耐受性良好,大多數 DKN-01 相關事件爲低等級(1/2 級)
Part B of the DeFianCe Study of DKN-01 plus bevacizumab and chemotherapy in CRC patients is ongoing, with enrollment expanded to 180 patients and expected to be completed in late Q3/early Q4 2024. The Company expanded the randomized controlled Part B of the DeFianCe study from 130 to 180 patients and included PFS in the subpopulation of patients with left-sided CRC as an additional primary endpoint. The Company expects to complete enrollment in late Q3 or early Q4 2024 with data expected in mid-2025. As of May 8, 2024, 114 patients have enrolled in Part B.
Completion of enrollment in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer. Part C of the DisTinGuish study (NCT0436380) is a Phase 2, randomized, open-label, multicenter study of DKN-01 in combination with tislelizumab and chemotherapy in first-line patients with advanced gastroesophageal adenocarcinoma. Part C enrolled 170 first-line, HER2-negative patients randomized 1:1 to evaluate DKN-01 in combination with tislelizumab and SOC chemotherapy, compared to tislelizumab and SOC chemotherapy alone. The primary objective is PFS in DKK1-high and in all patients. Secondary objectives of Part C include OS and ORR as measured by RECIST v1.1 in DKK1-high and in all patients. The Company expects to report initial data from Part C of the DisTinGuish study in the second half of 2024 or early 2025 when the PFS data are mature.
針對結直腸癌患者的 DKN-01 加貝伐珠單抗和化療的 Defiance 研究的B部分正在進行中,入組人數擴大到180名患者,預計將於2024年第四季度末/第四季度初完成。該公司將DeFiance研究的隨機對照B部分從130名患者擴大到180名患者,並將PFS納入左側結直腸癌患者亞群,作爲另一個主要終點。該公司預計將在2024年第三季度末或第四季度初完成註冊,數據預計將於2025年中期完成。截至 2024 年 5 月 8 日,已有 114 名患者加入了 B 部分。
完成了區分研究的隨機對照C部分的入組,該研究評估 DKN-01 與百濟神州的抗PD-1抗體替雷利珠單抗聯合以及晚期胃食管交界處和胃癌患者的化療。區分研究的C部分 (NCT0436380)是一項針對晚期胃食管腺癌一線患者的 DKN-01 聯合替雷利珠單抗和化療的 2 期隨機、開放標籤、多中心研究。與單獨使用替雷利珠單抗和 SOC 化療相比,C 部分招收了 170 名一線 HER2 陰性患者,對 DKN-01 與替雷利珠單抗和 SOC 化療聯合進行評估。主要目標是高DK1和所有患者的PFS。C部分的次要目標包括根據RECIST v1.1在DKK1和所有患者中測得的OS和ORR。該公司預計將在2024年下半年或2025年初PFS數據成熟時報告區分研究C部分的初始數據。
Selected First Quarter 2024 Financial Results
Net Loss was $13.8 million for the first quarter 2024, compared to $41.9 million for the same period in 2023. The decrease was primarily due to $29.6 million of in-process research and development ("IPR&D") expense associated with the Flame merger in January 2023.
2024 年第一季度精選財務業績
2024年第一季度的淨虧損爲1,380萬美元,而2023年同期爲4190萬美元。下降的主要原因是與2023年1月Flame合併相關的2960萬美元在制研發(“IPR&D”)支出。
Research and development expenses were $11.3 million for the first quarter 2024, compared to $38.9 million for the same period in 2023. The decrease of $27.6 million was primarily due to $29.6 million of IPR&D associated with the Flame merger. In addition, there was a decrease of $0.4 million in manufacturing costs related to clinical trial material manufacturing campaigns and a decrease of $0.1 million in consulting fees associated with R&D activities. These decreases were partially offset by an increase of $2.0 million in clinical trial costs and an increase of $0.5 million in payroll and other related expenses due to an increase in headcount of our R&D full-time employees.
2024年第一季度的研發費用爲1,130萬美元,而2023年同期爲3,890萬美元。減少2760萬美元的主要原因是與Flame合併相關的2960萬美元的知識產權與開發。此外,與臨床試驗材料製造活動相關的製造成本減少了40萬美元,與研發活動相關的諮詢費用減少了10萬美元。由於我們的研發全職員工人數增加,臨床試驗成本增加了200萬美元,工資和其他相關費用增加了50萬美元,部分抵消了這些下降。
General and administrative expenses were $3.5 million for the first quarter 2024, compared to $3.8 million for the same period in 2022. The decrease was due to a decrease of $0.3 million in professional fees associated with our business development activities.
2024年第一季度的一般和管理費用爲350萬美元,而2022年同期爲380萬美元。下降是由於與我們的業務發展活動相關的專業費用減少了30萬美元。
Cash and cash equivalents totaled $54.9 million at March 31, 2024, exclusive of the $37.2 million net proceeds of the private placement completed in April 2024. Research and development incentive receivables, current portion, totaled $0.7 million at March 31, 2024.
截至2024年3月31日,現金及現金等價物總額爲5,490萬美元,其中不包括2024年4月完成的私募的3,720萬美元淨收益。截至2024年3月31日,研發激勵應收賬款的流動部分總額爲70萬美元。
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
關於 Leap Therap
Leap Therapeutics(納斯達克股票代碼:LPTX)專注於開發靶向和免疫腫瘤學療法。Leap 最先進的臨床候選藥物 DKN-01 是一種靶向 Dickkopf-1 (DKK1) 蛋白的人源化單克隆抗體。DKN-01 正在開發用於食管胃癌、婦科癌和結直腸癌患者。FL-301 是一種靶向 Claudin18.2 的人源化單克隆抗體,正在開發用於胃癌和胰腺癌患者。Leap 還有針對 Claudin18.2/CD137 和 GDF15 的臨床前抗體項目。有關 Leap Therapeutics 的更多信息,請訪問 http://www.leaptx.com 或者查看我們向美國證券交易委員會提交的公開文件,這些文件可通過 EDGAR 獲得 http://www.sec.gov 或者通過 https://investors.leaptx.com/。
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements.
前瞻性陳述
本新聞稿包含聯邦證券法所指的前瞻性陳述。此類陳述基於Leap管理層當前的計劃、估計和預期,這些計劃、估計和預期存在各種風險和不確定性,可能導致實際業績與此類陳述存在重大差異。納入前瞻性陳述不應被視爲表示此類計劃、估計和預期將得到實現。諸如 “預期”、“期望”、“項目”、“打算”、“相信”、“可能”、“應該”、“計劃”、“可以”、“繼續”、“目標”、“考慮”、“估計”、“預測”、“指導”、“預測”、“可能”、“可能”、“追求”、“可能” 等詞語和術語以及類似實質內容的詞語和術語用於討論未來計劃、行動或事件時表示前瞻性陳述。
All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates; the anticipated expansion of the DeFianCe study and timing for completion of clinical trials and release of clinical trial data and the expectations surrounding the outcomes thereof; Leap's future clinical or preclinical product development plans for any of Leap's product candidates; Leap's estimations of projected cash runway; the anticipated closing date of the private placement; the amount of proceeds to be received by Leap and Leap's intended use of proceeds from the private placement; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully execute its clinical trials and the timing of enrollment in and cost of such clinical trials; (ii) the results of Leap's clinical trials and pre-clinical studies; (iii) Leap's ability to successfully enter into new strategic partnerships for DKN-01 or any of its other programs and to maintain its ongoing collaborations with BeiGene, NovaRock and Adimab; (iv) whether any Leap clinical trials and products will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; (v) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Leap's traded securities; and (vi) that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by global conflict, or supply chain related issues. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or Implied) are made about the accuracy of any such forward-looking statements. Leap may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Leap's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Leap, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof.
除歷史事實以外的所有陳述,包括有關Leap候選產品的潛在安全性、有效性以及監管和臨床進展的陳述;DeFiance研究的預期擴展、完成臨床試驗和發佈臨床試驗數據的時間以及對其結果的預期;Leap對任何候選產品的未來臨床或臨床前產品開發計劃;Leap對預計現金流的估計;私募的預計截止日期;金額Leap和Leap對私募收益的預期用途所獲得的收益以及上述任何基礎的任何假設均爲前瞻性陳述。可能導致實際結果與 Leap 的計劃、估計或預期存在重大差異的重要因素可能包括但不限於:(i) Leap 成功執行臨床試驗的能力以及此類臨床試驗的註冊時間和成本;(ii) Leap 臨床試驗和臨床前研究的結果;(iii) Leap 成功爲 DKN-01 或其任何其他項目建立新的戰略伙伴關係並維持其持續合作的能力與百濟神州、NovaRock 和 Adimab 合作;(iv) 是否有 Leap臨床試驗和產品將獲得美國食品藥品監督管理局或同等外國監管機構的批准;(v)通貨膨脹、貨幣利率和利率波動以及Leap交易證券市場價格波動的風險;(vi)臨床試驗、實驗室運營、生產活動和其他研究的啓動、進行和完成可能會受到全球衝突或供應鏈相關問題的不利影響或影響。新的風險和不確定性可能會不時出現,因此不可能預測所有的風險和不確定性。對於任何此類前瞻性陳述的準確性,不作任何陳述或保證(明示或暗示)。Leap實際上可能無法實現此類前瞻性陳述中披露的預測,您不應過分依賴此類前瞻性陳述。此類前瞻性陳述受許多重大風險和不確定性的影響,包括但不限於Leap向美國證券交易委員會提交的最新10-K表年度報告中 “風險因素” 標題下列出的風險和不確定性,以及隨後向美國證券交易委員會提交的文件中對潛在風險、不確定性和其他重要因素的討論。任何前瞻性陳述僅代表其發表之日。除非法律要求,否則Leap及其任何關聯公司、顧問或代表均不承擔任何義務公開更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。不應依賴這些前瞻性陳述來代表Leap自本文發佈之日起的任何日期的觀點。
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
聯繫人:
道格拉斯·E·昂西
總裁兼首席執行官
Leap Therapeutics
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com
馬修·德揚
投資者關係
Argot Par
212-600-1902
leap@argotpartners.com
Leap Therapeutics, Inc |
||||||||||
Consolidated Statements of Operations |
||||||||||
(in thousands, except share and per share amounts) |
||||||||||
(Unaudited) |
||||||||||
Three Months Ended March 31 |
||||||||||
2024 |
2023 |
|||||||||
Operating expenses: |
||||||||||
Research and development |
$ 11,299 |
$ 38,942 |
||||||||
General and administrative |
3,526 |
3,784 |
||||||||
Total operating expenses |
14,825 |
42,726 |
||||||||
Loss from operations |
(14,825) |
(42,726) |
||||||||
Interest income |
775 |
848 |
||||||||
Australian research and development incentives |
246 |
272 |
||||||||
Foreign currency loss |
(16) |
(307) |
||||||||
Change in fair value of Series X preferred stock warrant liability |
- |
50 |
||||||||
Net loss |
$ (13,820) |
$ (41,863) |
||||||||
Net loss per share |
||||||||||
Basic and Diluted |
$ (0.51) |
$ (3.24) |
||||||||
Weighted average common shares outstanding |
||||||||||
Basic and diluted |
27,014,100 |
12,934,427 |
Leap 療法公司 |
||||||||||
合併運營報表 |
||||||||||
(以千計,股票和每股金額除外) |
||||||||||
(未經審計) |
||||||||||
截至 3 月 31 日的三個月 |
||||||||||
2024 |
2023 |
|||||||||
運營費用: |
||||||||||
研究和開發 |
11,299 美元 |
38,942 美元 |
||||||||
一般和行政 |
3,526 |
3,784 |
||||||||
運營費用總額 |
14,825 |
42,726 |
||||||||
運營損失 |
(14,825) |
(42,726) |
||||||||
利息收入 |
775 |
848 |
||||||||
澳大利亞的研發激勵措施 |
246 |
272 |
||||||||
外幣損失 |
(16) |
(307) |
||||||||
X系列優先股認股權證負債公允價值的變化 |
- |
50 |
||||||||
淨虧損 |
美元 (13,820) |
美元 (41,863) |
||||||||
每股淨虧損 |
||||||||||
基礎版和稀釋版 |
美元 (0.51) |
美元 (3.24) |
||||||||
已發行普通股的加權平均值 |
||||||||||
基本款和稀釋版 |
27,014,100 |
12,934,427 |
Leap Therapeutics, Inc |
||||||||||
Consolidated Balance Sheets |
||||||||||
(in thousands, except share and per share amounts) |
||||||||||
March 31, |
December 31, |
|||||||||
2024 |
2023 |
|||||||||
Assets |
||||||||||
Current assets: |
||||||||||
Cash and cash equivalents |
$ 54,921 |
$ 70,643 |
||||||||
Research and development incentive receivable |
738 |
771 |
||||||||
Prepaid expenses and other current assets |
526 |
183 |
||||||||
Total current assets |
56,185 |
71,597 |
||||||||
Property and equipment, net |
- |
5 |
||||||||
Right of use assets, net |
577 |
257 |
||||||||
Research and development incentive receivable, net of current portion |
245 |
- |
||||||||
Deferred costs |
39 |
- |
||||||||
Deposits |
917 |
966 |
||||||||
Total assets |
$ 57,963 |
$ 72,825 |
||||||||
Liabilities and Stockholders' Equity |
||||||||||
Current liabilities: |
||||||||||
Accounts payable |
$ 5,951 |
$ 6,465 |
||||||||
Accrued expenses |
4,056 |
5,957 |
||||||||
Lease liability - current portion |
430 |
262 |
||||||||
Total current liabilities |
10,437 |
12,684 |
||||||||
Non current liabilities: |
||||||||||
Lease liability, net of current portion |
154 |
- |
||||||||
Total liabilities |
10,591 |
12,684 |
||||||||
Stockholders' equity: |
||||||||||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; |
- |
- |
||||||||
Common stock, $0.001 par value; 240,000,000 shares authorized; 25,603,471 and 25,565,414 |
26 |
26 |
||||||||
Additional paid-in capital |
460,868 |
459,591 |
||||||||
Accumulated other comprehensive income (loss) |
(120) |
106 |
||||||||
Accumulated deficit |
(413,402) |
(399,582) |
||||||||
Total stockholders' equity |
47,372 |
60,141 |
||||||||
Total liabilities and stockholders' equity |
$ 57,963 |
$ 72,825 |
Leap 療法公司 |
||||||||||
合併資產負債表 |
||||||||||
(以千計,股票和每股金額除外) |
||||||||||
3月31日 |
十二月三十一日 |
|||||||||
2024 |
2023 |
|||||||||
資產 |
||||||||||
流動資產: |
||||||||||
現金和現金等價物 |
54,921 美元 |
70,643 美元 |
||||||||
應收研發激勵金 |
738 |
771 |
||||||||
預付費用和其他流動資產 |
526 |
183 |
||||||||
流動資產總額 |
56,185 |
71,597 |
||||||||
財產和設備,淨額 |
- |
5 |
||||||||
使用權資產,淨額 |
577 |
257 |
||||||||
應收研發激勵金,扣除流動部分 |
245 |
- |
||||||||
遞延費用 |
39 |
- |
||||||||
存款 |
917 |
966 |
||||||||
總資產 |
57,963 美元 |
72,825 美元 |
||||||||
負債和股東權益 |
||||||||||
流動負債: |
||||||||||
應付賬款 |
5,951 美元 |
6,465 美元 |
||||||||
應計費用 |
4,056 |
5,957 |
||||||||
租賃負債-本期部分 |
430 |
262 |
||||||||
流動負債總額 |
10,437 |
12,684 |
||||||||
非流動負債: |
||||||||||
租賃負債,扣除流動部分 |
154 |
- |
||||||||
負債總額 |
10,591 |
12,684 |
||||||||
股東權益: |
||||||||||
優先股,面值0.001美元;授權1,000萬股; |
- |
- |
||||||||
普通股,面值0.001美元;授權240,000,000股;25,603,471和25,565,414股 |
26 |
26 |
||||||||
額外的實收資本 |
460,868 |
459,591 |
||||||||
累計其他綜合收益(虧損) |
(120) |
106 |
||||||||
累計赤字 |
(413,402) |
(399,582) |
||||||||
股東權益總額 |
47,372 |
60,141 |
||||||||
負債和股東權益總額 |
57,963 美元 |
72,825 美元 |
Leap Therapeutics, Inc |
||||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||||
(in thousands) |
||||||||||
(Unaudited) |
||||||||||
Three Months Ended March 31, |
||||||||||
2024 |
2023 |
|||||||||
Cash used in operating activities |
$ (15,516) |
$ (12,700) |
||||||||
Cash provided by investing activities |
- |
49,317 |
||||||||
Cash provided by (used in) financing activities |
29 |
(29) |
||||||||
Effect of exchange rate changes on cash and cash equivalents |
(235) |
(50) |
||||||||
Net increase (decrease) in cash and cash equivalents |
(15,722) |
36,538 |
||||||||
Cash and cash equivalents at beginning of period |
70,643 |
65,500 |
||||||||
Cash and cash equivalents at end of period |
$ 54,921 |
$ 102,038 |
Leap 療法公司 |
||||||||||
簡明合併現金流量表 |
||||||||||
(以千計) |
||||||||||
(未經審計) |
||||||||||
截至3月31日的三個月 |
||||||||||
2024 |
2023 |
|||||||||
用於經營活動的現金 |
$ (15,516) |
美元 (12,700) |
||||||||
投資活動提供的現金 |
- |
49,317 |
||||||||
由(用於)融資活動提供的現金 |
29 |
(29) |
||||||||
匯率變動對現金和現金等價物的影響 |
(235) |
(50) |
||||||||
現金和現金等價物的淨增加(減少) |
(15,722) |
36,538 |
||||||||
期初的現金和現金等價物 |
70,643 |
65,500 |
||||||||
期末的現金和現金等價物 |
54,921 美元 |
102,038 美元 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-reports-first-quarter-2024-financial-results-302142971.html
SOURCE Leap Therapeutics, Inc.
來源 Leap Therapeutics, Inc
譯文內容由第三人軟體翻譯。